Veru’s (VERU) “Buy” Rating Reaffirmed at HC Wainwright

Veru (NASDAQ:VERU)‘s stock had its “buy” rating reissued by research analysts at HC Wainwright in a note issued to investors on Friday,Benzinga reports. They presently have a $3.00 price objective on the stock. HC Wainwright’s price target would indicate a potential upside of 376.19% from the stock’s previous close.

Separately, Oppenheimer restated an “outperform” rating and set a $5.00 target price on shares of Veru in a report on Tuesday, November 5th.

Veru Stock Down 6.0 %

Shares of Veru stock opened at $0.63 on Friday. Veru has a 12-month low of $0.36 and a 12-month high of $1.92. The stock has a market capitalization of $92.22 million, a P/E ratio of -1.31 and a beta of -0.50. The company has a 50-day simple moving average of $0.74 and a 200 day simple moving average of $0.82.

Veru (NASDAQ:VERU) last posted its quarterly earnings data on Monday, December 16th. The company reported ($0.06) earnings per share for the quarter, topping the consensus estimate of ($0.07) by $0.01. Veru had a negative net margin of 376.38% and a negative return on equity of 115.99%. On average, equities analysts anticipate that Veru will post -0.3 earnings per share for the current year.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of VERU. Perceptive Advisors LLC raised its stake in shares of Veru by 26.5% during the second quarter. Perceptive Advisors LLC now owns 7,063,277 shares of the company’s stock worth $5,942,000 after buying an additional 1,478,578 shares during the last quarter. PVG Asset Management Corp bought a new stake in shares of Veru during the 2nd quarter valued at $474,000. Bank of New York Mellon Corp raised its position in shares of Veru by 1,718.2% during the 2nd quarter. Bank of New York Mellon Corp now owns 443,782 shares of the company’s stock valued at $373,000 after acquiring an additional 419,374 shares during the last quarter. Choreo LLC lifted its stake in shares of Veru by 261.3% in the 2nd quarter. Choreo LLC now owns 332,050 shares of the company’s stock valued at $292,000 after purchasing an additional 240,134 shares during the period. Finally, Squarepoint Ops LLC acquired a new stake in shares of Veru during the second quarter worth $161,000. Institutional investors own 47.16% of the company’s stock.

Veru Company Profile

Veru Inc, a late clinical stage biopharmaceutical company, focuses on developing medicines for treatment of metabolic diseases, oncology, and acute respiratory distress syndrome (ARDS). Its marketed products comprise FC2 female condom for the dual protection against unplanned pregnancy and the transmission of sexually transmitted infections.